3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
8
Liver Neoplasms
5
Carcinoma, Hepatocellular
4
Lung Neoplasms
3
Squamous Intraepithelial Lesions
2
Prostatic Neoplasms
2
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Unresectable Pancreatic Cancer
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Rectal Neoplasms
1
Pancreatic Ductal Adenocarcinoma
1
Neoplasm Metastasis
1
Melanoma
1
Lymphatic Metastasis
1
Liver, Cancer of, Non-Resectable
1
Laryngeal Neoplasms
1
Hilus Pulmonary Neoplasms
1
Head and Neck Neoplasms
1
HIV Seropositivity
1
Gallbladder Neoplasms
1
Extremities Neoplasms
1
Esophageal Neoplasms
1
Colorectal Liver Metastases
1
Carcinoma, Renal Cell
1
Interventions
Cisplatin
90
Fluorouracil
76
Radiotherapy
63
Paclitaxel
58
Docetaxel
49
Oxaliplatin
48
Irinotecan
42
Leucovorin
32
Capecitabine
31
Carboplatin
27
Radiation
21
Surgical Procedures, Operative
20
Esophagectomy
20
pembrolizumab
15
Neoadjuvant Therapy
15
Bevacizumab
15
Cetuximab
13
Drug Therapy
12
Epirubicin
11
Chemotherapy, Adjuvant
9
S 1 (combination)
8
Magnetic Resonance Spectroscopy
8
Gemcitabine
8
Trastuzumab
7
Nivolumab
7
Erlotinib Hydrochloride
7
Surveys and Questionnaires
6
Panitumumab
6
Immunohistochemistry
6
Chemoradiotherapy
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Esophageal Neoplasms
×
Electroporation
×
Clear all
NCT02430701
2021-09-05
IRE
Fuda Cancer Hospital, Guangzhou
Phase NA
Completed
30 enrolled